European Journal of Clinical Microbiology & Infectious Diseases最新文献

{"title":"Antibiotic practices in kidney transplant recipients with urosepsis are associated with treatment outcomes - a post-hoc analysis of an observational study.","authors":"Tomasz Królicki, Tobiasz Kudla, Anna Królicka, Klaudia Bardowska, Krzysztof Letachowicz, Ryszard Gawda, Tomasz Czarnik, Magdalena Krajewska, Dorota Kamińska","doi":"10.1007/s10096-025-05181-x","DOIUrl":"https://doi.org/10.1007/s10096-025-05181-x","url":null,"abstract":"<p><p>This study is a post-hoc analysis of a previously published observational study. The aim is to characterize the epidemiology, etiology and antibiotic practices in KTRs admitted due to urosepsis (US) and urinary tract infection (UTI) to a tertiary transplantation center between the period 2014-2019.The two study groups consisted of 101 KTRs with a primary episode of US and 100 randomly selected KTRs hospitalized for UTI as a control group. A post-hoc analysis of clinical and microbiological data was performed, and a local microbiological map was created.The estimated yearly incidence of US in the study population was 21.1 (95% CI: 15.3-26.9) cases per 1000 KTRs per year. Urosepsis accounted for 85% of all sepsis cases. The most common causative pathogen in both groups was Escherichia coli. In 46% and 11% of US and UTI cases, initial empiric antibiotic therapy had to be escalated until day 3 due to lack of clinical response or proven bacterial resistance. This delay in appropriate antibiotic treatment in the US group was significantly associated with mortality (OR = 10.1 with p = 0.021), need for acute renal replacement therapy (OR = 4.73 with p = 0.012) and non-recovery from AKI (OR = 3.18 with p = 0.031). After discharge from hospital, almost 60% of all study subjects received a prophylactic antibiotic course for prevention of UTI recurrence, which did not translate into a lower frequency of readmission due to UTI in a multivariable analysis.US is a common insult that contributes to graft failure in KTRs. We recommend adjusting US and UTI treatments to center-specific microbiological maps in order to optimize treatment outcomes, reduce development of antibiotic resistance, and avoid unnecessary exposure to nephrotoxic antimicrobial drugs.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144247053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mobile genetic elements of global Escherichia coli ST131 clades with carbapenemases.","authors":"Gisele Peirano, Yasufumi Matsumara, Johann D D Pitout","doi":"10.1007/s10096-025-05187-5","DOIUrl":"https://doi.org/10.1007/s10096-025-05187-5","url":null,"abstract":"<p><strong>Introduction: </strong>Escherichia coli ST131 is an important clone linked with carbapenemases. Limited data is available about the international distribution of ST131 clades and mobile genetic elements (MGEs) linked with carbapenemases.</p><p><strong>Methods: </strong>Short and long read WGS were performed on ST131 with carbapenemases (n=53) obtained from 21 countries (2010-19). We fully assembled 51 of the carbapenenemase containing plasmids that were grouped into MOB-clusters using MOB-suite v3.1.9.</p><p><strong>Results: </strong>KPCs (n=37) were the most frequent carbapenemases followed by NDMs (n=8), OXA-48-like (n=7), VIMs (n=1) and IMPs (n=2). ST131 subclades were linked with different carbapenemases and clade C dominated the population structure. Plasmids with bla_KPCs (n=35) belonged to eight MOB-clusters that included IncU, IncF, ColRNAI, IncN1, IncR, pKPC-CAV1193, Col-pHAD28; bla_NDMs plasmids (n=7) belonged to four MOB-clusters that included IncF, IncX3, IncC, IncN2; bla_OXA-48-like plasmids (n=6) belonged to six MOB-clusters that included IncL. IncM1, Col(pHAD28), ColKP3, IncF, IncX3; bla_IMPs plasmids (n=2) belonged to IncN1 and IncC, while the bla_VIM-1 (n=1) plasmid belonged to IncC. Multiple transposable and antimicrobial resistance determinants were harboured on these plasmids.</p><p><strong>Conclusions: </strong>The global spread of carbapenemase genes in ST131 clades were driven by multiple underlying mechanisms, including the local and international spread of highly similar plasmids as well as diverse plasmids, within the same geographical locations. This study provided references for future ST131 genomic studies on MGEs linked with carbapenemases.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144247054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Performance of a novel DiaRD-HCV RNA RTqPCR kit for quantification of HCV RNA in clinical samples.","authors":"Ulker Cuhaci, Bengul Durmaz, Hande Toptan, Mehmet Koroglu, Derya Mutlu, Dilek Colak, Rıza Durmaz","doi":"10.1007/s10096-025-05179-5","DOIUrl":"https://doi.org/10.1007/s10096-025-05179-5","url":null,"abstract":"<p><strong>Purpose: </strong>Quantitative detection of hepatitis C virus (HCV) RNA is essential for diagnosis of chronic infection and monitoring the HCV levels in patients under treatment. In this study, we aimed to evaluate the performance characteristics and comparability of a novel DiaRD-HCV RT qPCR kit (Diagen Lts, Ankara, Turkey) with Artus HCV QS-RGQ kit and the NeuMoDx HCV Quant Test in clinical samples.</p><p><strong>Methods: </strong>A total of 240 plasma samples, 86 HCV RNA positive and 154 negative, were used for comparison. Intra-assay and inter-assay reproducibility tests of the novel kit were carried out on clinical samples having HCV RNA loads of 1.42 × 10³ IU/µl, 1.40 × 10⁴ IU/ml, and 5.10 × 10⁵ IU/ml. HCV genotypes 1b, 2a, 2b, 3a, 4, 5, and 6 were tested by the novel system.</p><p><strong>Results: </strong>DiaRD HCV RTqPCR kit demonstrated a sensitivity of 98.8%, a specificity of 100%, and an accuracy of 99.6%. Linear regression analysis demonstrated strong correlation (R² = 0.915) on paired quantitative results. There was a good agreement between the novel kit and two comparator kits, with an overall mean difference of -0.12 log10 IU/ml obtained by Bland-Altman analysis. According to different viral loads, the intra-assay, inter-assay, and inter-load coefficients of variations (CVs) of the novel kit ranged from 5.31% to 11.73%, from 9.31% to 17.16%, and from 4.25% to 15.38% repeats. P-values were between 0.3 and 0.9, confirming no significant variations in the quantitative results of the reproducibility experiments. All genotypes tested were detected and quantitated with the mean differences between 0.01 and 0.62 log10 IU/ml. The primers and probe used in the novel kit did not result in any false-positive results with other pathogens.</p><p><strong>Conclusions: </strong>These results highlight the potential utility of the DiaRD HCV RTqPCR kit for quantitation and monitoring of HCV RNA in patients.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144224780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiological characteristics of Helicobacter pylori infection and antibiotic resistance in urban areas of Guangdong Province, China: a multi-center, cross-sectional surveillance.","authors":"Luhua Xian, Yuting Si, Luan Luan, Jinxin Lai, Jiawei Tang, Liang Wang","doi":"10.1007/s10096-025-05105-9","DOIUrl":"10.1007/s10096-025-05105-9","url":null,"abstract":"<p><strong>Purpose: </strong>Helicobacter pylori (H. pylori) infection is widespread globally and can cause serious gastrointestinal complications, including gastric cancer. This study assesses the prevalence and antibiotic resistance of H. pylori in Guangdong, one of China's most developed provinces.</p><p><strong>Methods: </strong>A multi-center, cross-sectional study was conducted across six cities in Guangdong provinces, that is, Guangzhou, Shenzhen, Heyuan, Foshan, Yunfu, and Zhaoqing. Non-invasive gastric fluid samples were collected via the string test, and H. pylori infection and antibiotic resistance were detected using quantitative PCR. Risk factors for infection were analyzed.</p><p><strong>Results: </strong>Of 1,764 participants, 444 (25.17%) tested positive for H. pylori, with the highest infection rate in Foshan (29.81%). Antibiotic resistance testing of these 444 infected individuals revealed that, except for levofloxacin resistance in Yunfu (14.29%), clarithromycin resistance in Yunfu and resistance to other antibiotics in all cities exceeded the 15% threshold. Infection rates were significantly higher in males (OR 1.29, 95% CI 1.03-1.60, p = 0.03) and obese individuals (OR 2.04, 95% CI 1.04-3.91, p = 0.03), with obesity identified as an independent risk factor.</p><p><strong>Conclusion: </strong>This study provides a comprehensive update on the prevalence, antibiotic resistance, and risk factors of H. pylori infection in Guangdong, offering valuable insights for public health strategies aimed at improving diagnosis and treatment.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":"1305-1312"},"PeriodicalIF":3.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interpretation of pathogenicity and clinical features of multiple pathogens in pediatric lower respiratory tract infections by tNGS RPTM analysis.","authors":"Yujia Xiao, Dekyi, Xia Wang, Shuwen Feng, Yiyu Yang, Junwen Zheng, Dongchi Zhao","doi":"10.1007/s10096-025-05094-9","DOIUrl":"10.1007/s10096-025-05094-9","url":null,"abstract":"<p><strong>Background: </strong>To characterize the epidemiology of pathogens in children with lower respiratory tract infections (LRTI) using targeted next-generation sequencing (tNGS), assess the correlation between reads per ten million (RPTM) of co-detected pathogens, identify common co-detection patterns, and explore their clinical significance.</p><p><strong>Methods: </strong>Children aged 29 days to 14 years hospitalized for LRTI at the Department of Pediatrics, Zhongnan Hospital of Wuhan University, from April 2023 to August 2024 were included. Bronchoalveolar lavage fluid (BALF) or nasopharyngeal swab (NS) samples were tested for pathogens using tNGS, and clinical data were collected. The data and RPTM were statistically analyzed based on lung X-ray and CT scan results, classifying cases as pneumonia or lung consolidation/pulmonary atelectasis (LC/PA).</p><p><strong>Results: </strong>Among 1118 children, the highest pathogen detection rate was Mycoplasma pneumoniae (MP) at 60.20%, followed by Haemophilus influenzae (HI) at 42.40% and Streptococcus pneumoniae (SP) at 35.42%. In children under 4 years old, common pathogens were HI, Rhinovirus (RhV), and Respiratory syncytial virus (RSV). For those over 4 years old, MP and HI were predominant. In common pneumonia cases, MP, HI, and RhV were frequent, with MP being the primary pathogen in LC/PA. 80.70% of respiratory samples detected two or more pathogens, and viruses were more frequently detected in NS than in BALF. Correlation analysis showed that MP RPTM was negatively correlated with other co-detected pathogens' RPTM, SP was negatively correlated with RSV but positively correlated with Influenza virus (flu virus), HI was positively correlated with Adenovirus (ADV) and flu virus, RhV was negatively correlated with flu virus. Clinical characteristics of co-detected pathogens showed no significant differences in acute LRTI symptoms among different combinations.</p><p><strong>Conclusion: </strong>Co-detection of pathogens in children's LRTI using tNGS was common, with MP and bacterial infections being predominant. There were synergistic and competitive relationships between the RPTM of co-detected pathogens.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":"1313-1324"},"PeriodicalIF":3.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143630039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiological and clinical profiles of respiratory syncytial virus infections in hospitalized children: a retrospective cohort study utilizing targeted next-generation sequencing.","authors":"Chunyun Fu, Jialing Ruan, Lishai Mo, Jiangyang Zhao, Junming Lu, Ya Huang, Xuehua Hu, Qiang Huang, Yanhua Feng, Wenting Tang, Ning Zhu, Cuihong Lu, Xiangjun Lu, Ruting Chen, Guangbing Liu, Huiping Huang, Qifei Li, Jie Tan","doi":"10.1007/s10096-025-05112-w","DOIUrl":"10.1007/s10096-025-05112-w","url":null,"abstract":"<p><strong>Background: </strong>Respiratory syncytial virus (RSV) is a significant cause of respiratory infections in children. Currently, there is limited literature on the clinical use of pathogen-targeted sequencing technologies and the systematic analysis of RSV infections in hospitalized children. The primary objective of this research was to evaluate the infection status and clinical manifestations associated with RSV in these pediatric patients.</p><p><strong>Methods: </strong>Between July 2021 and November 2023, 5,021 children hospitalized due to respiratory infections or associated complications were enrolled at the Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region. Targeted next-generation sequencing (tNGS) was used to detect pathogens in their respiratory samples. Subsequently, the clinical data of children infected with RSV were systematically evaluated.</p><p><strong>Results: </strong>Of the 5,021 children hospitalized with respiratory infections, RSV was detected in 1,080, yielding a detection rate of 21.5%. Among RSV-positive patients, only 8.6% (93/1080) experienced single infections, while the majority, 91.4% (987/1080), had co-infections with other pathogens. Among the observed infection patterns, RSV-viral-bacterial co-infection was the most prevalent, occurring in 524 cases (48.5%), followed by RSV-viral co-infection in 141 cases (13.1%). Among children with RSV co-infections, 43 additional microorganisms were detected, with cytomegalovirus, Haemophilus influenzae, and Streptococcus pneumoniae being the most prevalent. Of the 1,080 children diagnosed with RSV, 172 (15.9%) required ICU admission for monitoring. The median duration of hospitalization for the 1080 children diagnosed with RSV infection was 8 days. Of these, 1025 (94.9%) patients recovered and were discharged following treatment, while 54 (5.0%) of the patients' family members requested voluntary discharge due to unsatisfactory outcomes or other reasons. Unfortunately, one child (0.1%) died despite receiving intensive medical treatment.</p><p><strong>Conclusion: </strong>Due to the high incidence of RSV infections and associated ICU admissions, there is a critical need for effective vaccine development to protect infants and children. This study presents a comprehensive analysis of hospitalized pediatric patients with RSV, examining infection patterns, clinical manifestations, laboratory findings, imaging characteristics, complications, and prognosis.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":"1391-1403"},"PeriodicalIF":3.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alkalihalobacillus clausii bacteremia after probiotic use for acute diarrhea: a case report.","authors":"Paola Andrea Gallego Aristizabal, Sebastián Peláez García, Javier Eduardo Caicedo Espinosa, Susana Montoya-Jaramillo, Isabel González-Tapias","doi":"10.1007/s10096-025-05115-7","DOIUrl":"10.1007/s10096-025-05115-7","url":null,"abstract":"<p><p>Alkalihalobacillus clausii (previously known as Bacillus clausii) is a spore-forming bacterium used as a probiotic due to its resistance to gastric acidity and intestinal conditions. It is marketed for managing acute diarrhea, though evidence of its efficacy and safety is limited. We present the case of an 87-year-old man with acute viral diarrhea treated with Alkalihalobacillus clausii, who developed septic shock with blood cultures confirming Alkalihalobacillus clausii bacteremia. Intensive care and daptomycin therapy led to clinical resolution.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":"1527-1529"},"PeriodicalIF":3.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early appropriate therapy with polymyxin B reduces the mortality in burn sepsis caused by carbapenem-resistant gram-negative bacteria: a retrospective analysis.","authors":"Nanhong Jiang, Weiguo Xie, Deyun Wang, Wei Wang","doi":"10.1007/s10096-025-05119-3","DOIUrl":"10.1007/s10096-025-05119-3","url":null,"abstract":"<p><strong>Objective: </strong>The prevalence of Carbapenem-Resistant Gram-Negative Bacteria (CR-GNB) is rapidly escalating, presenting a significant global public health concern. This study aims to evaluate the survival rate of early appropriate therapy with polymyxin B (PMB), and adverse drug reactions of PMB in treating severe burn sepsis caused by CR-GNB infections.</p><p><strong>Methods: </strong>We retrospectively analyzed 72 patients with severe burn sepsis caused by CR-GNB infections from January 1, 2018, to December 30, 2023. These patients received a treatment regimen based on PMB for at least three days. We collected data on the patient's clinical characteristics, microbiological results, details of PMB treatment, adverse drug reactions with PMB, and mortality. We compared the 30-day mortality rates between patients who received early appropriate therapy (the timely administration of an active antimicrobial agent within 48 h after the onset of infection) and those who underwent non-early appropriate therapy, multivariate Cox regression analysis was employed to evaluate factors impacting the 30-day survival rate of patients, and the adverse drug reactions caused by PMB were also analyzed.</p><p><strong>Results: </strong>Among the 72 patients with severe burn sepsis, the clinical effective rate was 69.4% (50/72), the 30-day all-cause mortality rate was 31.9% (23/72) and the 30-day sepsis-associated mortality rate was 27.8% (20/72). The adverse drug reactions of PMB included nephrotoxicity and skin pigmentation, with an incidence of 19.4% (14/72) and 15.3% (11/72), respectively. The patients who received early appropriate therapy had a lower mortality rate, lower SOFA scores and more wound infections compared to those who underwent non-early appropriate therapy (all P < 0.05). The univariate Cox regression analysis showed that age, hypertension, SOFA score at the time of sepsis diagnosis, and early appropriate therapy with PMB were associated with both 30-day all-cause mortality and sepsis-associated mortality in severely burned patients (all P < 0.05). Additionally, In the multivariate Cox regression analysis, early appropriate therapy with PMB was identified as an independent protective factor for both 30-day all-cause mortality (HR = 0.183 [95% CI 0.071-0.468], P < 0.001) and sepsis-associated mortality (HR = 0.150 [95% CI 0.054-0.414], P < 0.001) in severely burned patients.</p><p><strong>Conclusions: </strong>Polymyxin B is an effective option for burn sepsis patients in treating CR-GNB infections. Early appropriate therapy with PMB significantly improved the survival rate of severe burn sepsis patients infected with CR-GNB.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":"1433-1442"},"PeriodicalIF":3.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143771560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cefiderocol treatment for patients infected by Stenotrophomonas maltophilia, Burkholderia cepacia complex and Achromobacter spp.: subgroup analysis from the PERSEUS study.","authors":"Julian Torre-Cisneros, Ricard Ferrer, Carmen De La Fuente Martos, Jessica Sarda, A Javier Gonzalez Calvo, Stefano Verardi, Andreas Karas, Alex Soriano","doi":"10.1007/s10096-025-05109-5","DOIUrl":"10.1007/s10096-025-05109-5","url":null,"abstract":"<p><strong>Purpose: </strong>This subgroup analysis of the PERSEUS study aimed to describe the effectiveness of cefiderocol treatment in the early access programme in Spain in patients infected by Stenotrophomonas maltophilia, Burkholderia cepacia complex (Bcc) or Achromobacter species.</p><p><strong>Methods: </strong>In the retrospective, observational, multicentre PERSEUS study in Spain, the effectiveness and safety of cefiderocol treatment administered for at least 72 h up to 28 days in patients infected by Gram-negative bacteria, except Acinetobacter spp., in the early access programme was investigated. Patient demographics and baseline clinical characteristics, cefiderocol use, clinical cure at end of treatment, all-cause mortality at Day 28 were the main outcomes.</p><p><strong>Results: </strong>A total of 20 patients had S. maltophilia infections, and 14 patients had other rare glucose non-fermenters (Bcc 8, Achromobacter spp. 5, Ralstonia mannitolilytica 1). The median (interquartile range [IQR]) age was 60.5 (48.0-65.5) years and 49.5 (33.0-59.0) years for patients with S. maltophilia and other rare non-fermenters, respectively. The majority of patients had respiratory tract infections (S. maltophilia 55%; other rare non-fermenters 71.4%), and median (IQR) duration of cefiderocol treatment was 10.0 (6.5-13.5) days and 8.0 (6-14) days, respectively. Clinical cure rates were 70%, 62.5% and 80.0% for patients with S. maltophilia, Bcc and Achromobacter spp., respectively. Corresponding 28-day all-cause mortality rates were 30.0%, 37.5% and 40.0%, respectively. One patient with R. mannitolilytica had clinical cure and survived to Day 28.</p><p><strong>Conclusions: </strong>Cefiderocol is an important addition to the limited treatment options for patients infected by these rare glucose non-fermenting Gram-negative bacteria.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov: NCT05789199 (Registration date: 16 February 2023).</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":"1367-1374"},"PeriodicalIF":3.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12116654/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143700030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: Outpatient parenteral antibiotic therapy in non-cystic fibrosis lung transplant recipients: characteristics, efficacy and safety.","authors":"Bart Forier, Veronique Schaevers, Isabel Spriet, Charlotte Quintens, Stefanie Desmet, Saskia Bos, Pascal Van Bleyenbergh, Natalie Lorent, Laurens De Sadeleer, Laurent Godinas, Lieven J Dupont, Robin Vos","doi":"10.1007/s10096-025-05092-x","DOIUrl":"10.1007/s10096-025-05092-x","url":null,"abstract":"","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":"1491"},"PeriodicalIF":3.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12116694/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143630348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}